Investment Summary

Sun Pharma Invests In Caraco Pharmaceutical Laboratories

On February 23, 2011, Sun Pharma invested in life science company Caraco Pharmaceutical Laboratories

Investment Highlights
  • This is Sun Pharma’s 3rd transaction in the Life Science sector.
  • This is Sun Pharma’s 2nd transaction in the United States.
  • This is Sun Pharma’s 2nd transaction in Michigan.

Investment Summary
Date 2011-02-23
Target Caraco Pharmaceutical Laboratories
Sector Life Science
Investor(s) Sun Pharma
Deal Type Stake Purchase

Target

Caraco Pharmaceutical Laboratories

Detroit, Michigan, United States
Caraco Pharmaceutical Laboratories Ltd. is a developer, manufacturer and marketer of generic drugs for the prescription and over-the-counter markets.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Sun Pharma

Mumbai, India
Category Company
Founded 1983
Sector Life Science
Employees37,000
Revenue 477.6B INR (2024)
DESCRIPTION

Sun Pharma is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores, and gift/specialty stores. Sun Pharma was founded in 1983 and is based in Mumbai, India.

DEAL STATS #
Overall 6 of 14
Sector (Life Science) 3 of 9
Type (Stake Purchase) 5 of 5
State (Michigan) 2 of 2
Country (United States) 2 of 6
Year (2011) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-05-21 Taro Pharmaceutical Industries

Haifa Bay, Israel

Taro Pharmaceutical Industries is a manufacturer and developer of generic drugs and pharmaceutical components. Taro Pharmaceutical Industries was founded in 1950 and is based in Haifa, Israel.

Buy $454M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-20 DUSA Pharmaceuticals

Wilmington, Massachusetts, United States

DUSA Pharmaceuticals, Inc.® is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator.

Buy $230M
Mergr

Product

Company

Legal